
From 2013 to 2017, the population of US patients prescribed treatment for chronic hepatitis C virus (HCV) changed, becoming predominantly treatment-naïve and having received care in nonacademic centers.

From 2013 to 2017, the population of US patients prescribed treatment for chronic hepatitis C virus (HCV) changed, becoming predominantly treatment-naïve and having received care in nonacademic centers.

Hepatitis C virus treatment is often restricted in Medicaid patients. This analysis evaluates the clinical and cost impacts of treating all Medicaid patients versus the current status quo.

Published: February 16th 2017 | Updated:

Published: July 12th 2019 | Updated:

259 Prospect Plains Rd, Bldg H
 Cranbury, NJ 08512
© 2025 MJH Life Sciences®
All rights reserved.
